Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
267 Strategic optimization of BCMA and GPRC5D dual-targeted CAR T cells ...
GPRC5D x CD3 Bispecifics Available to License
The changing spectrum of infection with BCMA and GPRC5D targeting ...
Bispecific antibodies targeting BCMA or GPRC5D | PDF | Immunotherapy ...
Targeted Therapy for Multiple Myeloma: GPRC5D
GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to ...
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with ...
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T ...
Targeting GPRC5D for multiple myeloma therapy - PMC
GPRC5D is a target for the immunotherapy of multiple myeloma with ...
T-cell redirecting bispecific antibodies targeting BCMA for the ...
Frontiers | Targeting BCMA to Treat Multiple Myeloma: Updates From the ...
GPRC5D – A Promising Therapeutic Target for Multiple Myeloma-DIMA BIOTECH
GPRC5D as a novel target for the treatment of multiple myeloma: a ...
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple ...
抗多发性骨髓瘤抗体与人 GPRC5D 同二聚体的结合机制,Nature Communications - X-MOL
肿瘤免疫靶点 | GPRC5D - 知乎
SIM-0500(SIM-0500) - 药物靶点：BCMA x CD3 x GPRC5D_在研适应症：多发性骨髓瘤，骨髓瘤复发_专利_临床_研发
Efficacy and safety of chimeric antigen receptor T cells targeting BCMA ...
Frontiers | Bispecific antibodies for the treatment of relapsed ...
YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in ...
先声药业：GPRC5D/BCMA/CD3三抗IND获受理 Armstrong 2024年1月3日， 先声药业 注射用SIM0500的临床试验 ...
Frontiers | CAR-T cell therapy in multiple myeloma: Current limitations ...
Advancements in Multiple Myeloma Therapies: A Comprehensive Review by ...
全球首款：信达生物GPRC5D/BCMA/CD3三抗启动1/2期临床 Armstrong 2023年10月13日， 信达生物 在 ...
强生、信达生物研发GPRC5D/BCMA/CD3三抗 Armstrong 2022年8月25日， 强生 、 信达生物 的GPRC5D/BCMA ...
先声药业GPRC5D/BCMA/CD3三抗在美获批临床 3月11日， 先声药业 发布公告，其自主研发的抗肿瘤新药人源化GPRC5D/BCMA ...
With New Treatment Strategies, a Cure for Multiple Myeloma Is Now Possible
Full article: Emerging GPRC5D-Targeted therapies for multiple myeloma ...
BCMA/CD3 Bispecific Antibodies for Multiple Myeloma (MM) | Biopharma PEG
Figure 2 from Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody ...
(PDF) A T-cell-redirecting bispecific G-protein-coupled receptor class ...
Research Progress on BCMA-Targeted Therapies in Multiple Myeloma-DIMA ...
Frontiers | Bispecific antibodies in multiple myeloma treatment: A ...
Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple ...
GPRC5D, a promising therapeutic target for multiple myeloma - DIMA ...
(PDF) Mechanisms of antigen escape from BCMA- or GPRC5D-targeted ...
Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the ...
Frontiers | Beyond BCMA: the next wave of CAR T cell therapy in ...
罗氏GPRC5D × CD3双抗在中国获批临床 - 四川省医药保化品质量管理协会
Rakesh Popat教授详解新型BCMA/GPRC5D/CD3三抗I期研究成果丨EHA 2025
从Linvoseltamab最新临床数据公布，看BCMA/CD3双抗研究进展 - 知乎
QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager ...
BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with ...
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a ...
Frontiers | Deciphering the bone marrow microenvironment’s role in ...
结合BCMA、GPRC5D和CD3的多特异性抗体及其用途_专利查询 - 企查查
Immunotherapy Evolution Continues With Innovative Approaches to ...
British Journal of Haematology | Wiley Online Library
【Blood】多发性骨髓瘤中抗BCMA和GPRC5D双抗的疗效、安全性和耐药机制-MedSci.cn
Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple ...
A T-cell–redirecting bispecific G-protein–coupled receptor class 5 ...
信达生物 GPRC5D×BCMA×CD3 三抗国内获批临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
天广实BCMA/CD3/GPRC5D三抗MBS314获批临床，治疗多发性骨髓瘤
BCMACD3 Bispecific Antibodies for Multiple Myeloma (MM).pdf
GPRC5D, the next hot target for multiple myeloma immunotherapy ...
首创GPRC5D/CD3双抗Talquetamab获FDA批准上市！四线后复发/难治MM患者ORR达73.6%！ - 知乎
Figure 2 from Defining an Optimal Dual-Targeted CAR T-cell Therapy ...
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody ...
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory ...
Frontiers | Efficacy and safety of chimeric antigen receptor T cells ...
(PDF) Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for ...
国内首款：驯鹿医疗GPRC5D CAR-T启动临床 - 知乎
Anti-BCMA/GPRC5D CAR-T Cell Therapy - Multiple Myeloma Clinical Trials
靶向BCMA、GPRC5D和CD3的三特异性抗体的制作方法
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
全球首款！强生BCMA/CD3双抗获批上市，「王炸CP」能否攻下千亿市场？
CD3/CD19/BCMA 从肿瘤免疫到自身免疫性疾病的多面利器 - 知乎
BCMA/CD3丨从FDA第五款双抗看全球进展 2022年10月25日，FDA加速批准 强生 BCMA/CD3双抗TECVAYLI ...
全球首款BCMA/GPRC5D双特异的CAR-T细胞治疗成果发表医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
人源化小鼠模型：治疗多发性骨髓瘤(MM)，罗氏GPRC5D/CD3双抗在中国申报临床
Preclinical activity and determinants of response of the GPRC5DxCD3 ...
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma ...
GPRC5D, a potential target in multiple myeloma - iNEWS
CD3/BCMA/CD38三特异性抗体的制作方法
T cells with BCMA-CD3 antibodies effectively killed CHO-BCMA cells and ...
大佬下注，三抗开始发力|强生_新浪财经_新浪网
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or ...
SM0500(GPRC5D-BCMA-CD3)潜在多发性骨髓瘤BIC药物 - 2025年02月 - 行业研究数据 - 小牛行研
00176-5/asset/0ddf7c4c-331e-4d42-b808-c0f7bf1cc0b9/main.assets/gr2_lrg.jpg)
00176-5/asset/f0eab160-b14a-43f1-80dc-4105fe214088/main.assets/gr1_lrg.jpg)
